-
Amgen's DMab scores in trials
財富中文網 2009-07-10 11:42For the biotech, a new drug for bone cancer and osteoporosis could mean a big boost in revenue.By Alyssa AbkowitzAn Amgen trial drug -- called denosum...
-
安進新藥DMab在試驗中獲得成功
Alyssa Abkowitz 2009-07-10 11:41對于安進這家生物技術公司而言，一種治療骨癌和骨質疏松癥的新藥可能使其收入大大增加。作者：Alyssa Abkowitz安進（Amgen）的一種試用藥物——名為狄諾塞麥(denosumab)——于7月7日達到新的里程碑，這家生物技術公司宣布了該藥物針對骨癌的最新臨床試驗結果。對2000多名患者的試驗顯...
-
Eli Lilly's patent problem
Shelley DuBois 2010-08-24 01:54In 2009, Eli Lilly CEO John Lechleiter introduced a new drug development strategy called the Development Center of Excellence. The center's mission is...
-
Cisco's 'earth-shattering' announcement
Michael V. Copeland 2010-03-10 07:33For all you folks who had dreams of flying cars or Cisco (CSCO) announcing the purchase of EMC, what CEO John Chambers revealed Tuesday after weeks of...
-
Tim Geithner's latest headache
財富中文網 2009-07-16 11:27The treasury secretary's bid to rein in derivatives meets skepticism.By Carol J. LoomisThe Obama Administration has given itself two months to tell Co...
-
It's a phone! It's a browser! It's a wallet?
財富中文網 2009-11-09 05:41By Jessica ShamboraWill your cellphone soon become a proxy for your credit card? Zong and others are betting on it.If there’s one thing online merchan...
-
What's so great about working at Goldman?
Scott Cendrowski 2011-01-31 06:01The past 12 months have undoubtedly had Goldman Sachs (GS, Fortune 500) wishing for an invisibility cloak. The bank was sued by the SEC for trading ac...
-
Amazon's newest Kindle takes aim at newspapers
財富中文網 2009-05-08 02:07Amazon hopes to convert readers of magazines and newspapers to its newest e-book reader, the Kindle DX.By Jessica ShamboraThe question of whether Amaz...
-
科技業(yè)下一波浪潮：當大數(shù)據遇上生物學
ERIKA FRY，SY MUKHERJEE 2018-03-29 05:30去年12月，CVS提出以690億美元收購安進保險公司。今年1月，又有三大巨頭——亞馬遜、摩根大通和伯克謝爾哈撒韋表示要成立合資公司，降低共100萬左右員工的醫(yī)療成本并提高效果。之后3月，信諾保險表示將出資超過500億美元收購醫(yī)藥福利管理機構Express Scripts。為何近來醫(yī)療領域交易如此熱鬧...
-
制藥巨頭抱團能圓發(fā)財夢嗎？
Jen Wieczner 2014-02-17 07:46三年前，美國衛(wèi)生部門官員曾建議大型制藥公司共同開發(fā)治療藥物而不是相互競爭，當時這些公司的反應很矛盾。畢竟，大型制藥公司是競爭最激烈而且自我保護力度極大的領域之一。這些企業(yè)為本公司藥品的方方面面都申請了專利；對于侵害自己利益的對手，它們會予以回擊；專利到期后，為了阻擋競爭者，它們會發(fā)起價格戰(zhàn)。但現(xiàn)在，...
